search
Back to results

Evaluation of Safety and Efficacy of Pivot Balloon to Monitoring Acute RV Failure and Reduction of FTR

Primary Purpose

Functional Tricuspid Regurgitation

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Pivot Balloon Catheter
Sponsored by
Tau Pnu Medical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Functional Tricuspid Regurgitation focused on measuring FTR, RV failure, TauPnu

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adult males and females aged 20 years or above Target of Thoracic Surgery for TR,[11] and patients above the severe level on the criteria presented in the Classification of TR Grade (Tabe 1) based on echocardiogram, among those with TR, for whom a surgical treatment has been decided *patients with left valve disease, left ventricular failure, and pulmonary arterial hypertension in addition to functional tricuspid regurgitation can be selected An individual who voluntarily agreed to the participation in the clinical trial and signed the written consent An individual who is able to understand and comply with the instructions and who can participate in the period before the clinical trial Exclusion Criteria: Uncontrolled hyperthyroidism A recent formation of soft blood clot or embolic material Uncorrected coagulopathy Prohibition of anticoagulant agents Previous insertion of a device such as an Implantable Cardioverter Defibrillator (ICD) or a pacemaker Presence of malignant tumor or benign tumor such as myxoma in the heart Presence of a symptom of active infection Chronic pulmonary disease Congenital tricuspid valve insufficiency Severe pulmonary arterial hypertension with a right ventricular systolic pressure (RVSP) of 70 mmHg or higher Pregnant or lactating mother, or a female patient planning pregnancy during the period of clinical trial, or a female not using an approved contraceptive with the possibility of pregnancy Participation in another clinical trial 30 days prior to the screening In addition, anyone showing a clinical finding deemed to be unsuitable for the clinical trial by the Principal Investigator or the Investigator

Sites / Locations

  • Chungnam National University Sejong Hospital
  • Keimyung University Dongsan Hospital
  • Hallym University Medical Center
  • Pusan National University Yangsan Hospital
  • Chungnam National University Hospital (CNU Hospital)
  • Yeungnam University Hospital
  • Ulsan Hospital
  • Asan Medical Center
  • Bucheon Sejong Hospital
  • Samsung Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Pivot Balloon

Arm Description

mornitoring with transcatheter Tricuspid Regurgitation reduction system

Outcomes

Primary Outcome Measures

change of tricuspid regurgitation grade (1)
check the success of surgery /measure the size of the TR area
change of tricuspid regurgitation grade (2)
examine the changes in the severity of tricuspid valve insufficiency with Echocardiogram

Secondary Outcome Measures

change of tricuspid regurgitation valve hemodynamics
examine the changes in the severity of tricuspid valve insufficiency with Echocardiogram
evaluate the efficacy based on the function of early diagnosis (1)
examine tricuspid regurgitation intolerance
evaluate the efficacy based on the function of early diagnosis (2)
evaluate the technical success rate of the implantation and the technical feasibility of 'Pivot Balloon'

Full Information

First Posted
December 5, 2022
Last Updated
March 10, 2023
Sponsor
Tau Pnu Medical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05648838
Brief Title
Evaluation of Safety and Efficacy of Pivot Balloon to Monitoring Acute RV Failure and Reduction of FTR
Official Title
The Study for Evaluation of Safety and Efficacy of Pivot Balloon to Monitoring Acute RV Failure and Reduction of Functional Tricuspid Regurgitation : Multi-center, Open Label, Single Arm, Investigator Initiated Exploratory Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
July 19, 2021 (Actual)
Primary Completion Date
January 25, 2023 (Actual)
Study Completion Date
January 25, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tau Pnu Medical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Pivot Balloon to monitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
Detailed Description
The study for evaluation of safety and efficacy of Pivot Balloon to monitoring acute RV failure and reduction of Functional Tricuspid Regurgitation : multi-center, open label, single arm, investigator initiated exploratory pilot study

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Functional Tricuspid Regurgitation
Keywords
FTR, RV failure, TauPnu

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pivot Balloon
Arm Type
Experimental
Arm Description
mornitoring with transcatheter Tricuspid Regurgitation reduction system
Intervention Type
Device
Intervention Name(s)
Pivot Balloon Catheter
Intervention Description
mornitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
Primary Outcome Measure Information:
Title
change of tricuspid regurgitation grade (1)
Description
check the success of surgery /measure the size of the TR area
Time Frame
immediately after the procedure
Title
change of tricuspid regurgitation grade (2)
Description
examine the changes in the severity of tricuspid valve insufficiency with Echocardiogram
Time Frame
immediately after the procedure
Secondary Outcome Measure Information:
Title
change of tricuspid regurgitation valve hemodynamics
Description
examine the changes in the severity of tricuspid valve insufficiency with Echocardiogram
Time Frame
within 24 h of insertion
Title
evaluate the efficacy based on the function of early diagnosis (1)
Description
examine tricuspid regurgitation intolerance
Time Frame
within 24 h of insertion
Title
evaluate the efficacy based on the function of early diagnosis (2)
Description
evaluate the technical success rate of the implantation and the technical feasibility of 'Pivot Balloon'
Time Frame
within 24 h of insertion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult males and females aged 20 years or above Target of Thoracic Surgery for TR,[11] and patients above the severe level on the criteria presented in the Classification of TR Grade (Tabe 1) based on echocardiogram, among those with TR, for whom a surgical treatment has been decided *patients with left valve disease, left ventricular failure, and pulmonary arterial hypertension in addition to functional tricuspid regurgitation can be selected An individual who voluntarily agreed to the participation in the clinical trial and signed the written consent An individual who is able to understand and comply with the instructions and who can participate in the period before the clinical trial Exclusion Criteria: Uncontrolled hyperthyroidism A recent formation of soft blood clot or embolic material Uncorrected coagulopathy Prohibition of anticoagulant agents Previous insertion of a device such as an Implantable Cardioverter Defibrillator (ICD) or a pacemaker Presence of malignant tumor or benign tumor such as myxoma in the heart Presence of a symptom of active infection Chronic pulmonary disease Congenital tricuspid valve insufficiency Severe pulmonary arterial hypertension with a right ventricular systolic pressure (RVSP) of 70 mmHg or higher Pregnant or lactating mother, or a female patient planning pregnancy during the period of clinical trial, or a female not using an approved contraceptive with the possibility of pregnancy Participation in another clinical trial 30 days prior to the screening In addition, anyone showing a clinical finding deemed to be unsuitable for the clinical trial by the Principal Investigator or the Investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Seung-Whan Lee, PhD
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chungnam National University Sejong Hospital
City
Sejong
State/Province
Bodeum7ro
ZIP/Postal Code
30099
Country
Korea, Republic of
Facility Name
Keimyung University Dongsan Hospital
City
Daegu
State/Province
Dalseo-gu
ZIP/Postal Code
42601
Country
Korea, Republic of
Facility Name
Hallym University Medical Center
City
Anyang
State/Province
Dongan-gu
ZIP/Postal Code
14068
Country
Korea, Republic of
Facility Name
Pusan National University Yangsan Hospital
City
Yangsan
State/Province
Gyeongsangnamdo
ZIP/Postal Code
50602
Country
Korea, Republic of
Facility Name
Chungnam National University Hospital (CNU Hospital)
City
Daejeon
State/Province
Jung-gu
ZIP/Postal Code
35015
Country
Korea, Republic of
Facility Name
Yeungnam University Hospital
City
Daegu
State/Province
Nam-gu
ZIP/Postal Code
42415
Country
Korea, Republic of
Facility Name
Ulsan Hospital
City
Ulsan
State/Province
Nam-gu
ZIP/Postal Code
44686
Country
Korea, Republic of
Facility Name
Asan Medical Center
City
Seoul
State/Province
Songpa-gu
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Bucheon Sejong Hospital
City
Bucheon-si
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Evaluation of Safety and Efficacy of Pivot Balloon to Monitoring Acute RV Failure and Reduction of FTR

We'll reach out to this number within 24 hrs